Table 3.

Reasons for discontinuation of study drug

Primary reason for veliparib/placebo discontinuationPlacebo BID and carbo/paclitaxel (N = 53)Veliparib BID and carbo/paclitaxel (N = 105)
Completed treatment27 (50.9%)51 (48.6%)
Progression of disease13 (24.5%)22 (21.0%)
Adverse event related to progression2 (3.8%)8 (7.6%)
Adverse event not related to progression10 (18.9%)14 (13.3%)
Withdrew consent2 (3.8%)9 (8.6%)
Lost to follow-up01 (1.0%)
Other1 (1.9%)6 (5.7%)
  • Abbreviation: carbo, carboplatin.